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1 Present address: ARIAD Pharmaceuticals, Inc., CamN-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) has anti-tumorigenic properties, but its
direct cellular targets are unknown. Previously, we showed TPCK inhibited the PDKl-dependent
AGC kinases RSK, Akt and S6K1 without inhibiting PKA, ERK1/2, PI3K, and PDK1 itself. Here we show
TPCK-inhibition of the RSK-related kinases MSK1 and 2, which can be activated independently of
PDK1. Mass spectrometry analysis of RSK1, Aktl, S6K1 andMSK1 immunopuriﬁed from TPCK-treated
cells identiﬁed TPCK adducts on cysteines located in conserved activation loop Phenylalanine–
Cysteine (Phe–Cys) motifs. Mutational analysis of the Phe–Cys residues conferred partial TPCK resis-
tance. These studies elucidate a primary mechanism by which TPCK inhibits several AGC kinases,
inviting consideration of TPCK-like compounds in chemotherapy given their potential for broad
control of cellular growth, proliferation and survival.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ability of cells to perceive and appropriately respond to
their microenvironments is crucial to essentially all cellular pro-
cesses. Protein kinases are keymodulators and drivers of these pro-
cesses and therefore have become attractive targets for drug
discovery. The functionally diverse but structurally conserved fam-
ily of kinases termed the AGC kinases [1] (as they contain relatives
of protein kinase A (PKA), protein kinase G (PKG) and protein kinase
C (PKC)) includes isoforms of Akt (protein kinase B (PKB)) [2], p70
ribosomal S6 kinase (S6K) [3], p90 ribosomal S6 kinase (RSK) [4],
mitogen- and stress-activated protein kinase (MSK) [5], and ser-
um- and glucocorticoid-induced protein kinase (SGK) [6]. Despite
divergent regulation, these kinases are all activated by the common
kinase regulatory mechanism of phosphorylation at the autoinhib-
itory activation loop [7].
3-Phosphoinositide-dependent kinase 1 (PDK1) has been
shown to phosphorylate the activation loops of several AGCchemical Societies. Published by E
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bridge, MA 02139, USA.kinase family members [1,8]. Additionally PDK1 phosphorylates
its own activation loop [9]. Despite the emergence of PDK1 as
a critical regulator of multiple AGC kinases with oncogenic
potential, few studies have evaluated PDK1 as a potential target
for cancer therapy. However, PDK1’s value as a target for anti-
cancer therapy is certainly under consideration [10–12]. Previ-
ously we reported that TPCK disrupts PDK1 signaling to Akt,
S6K1, and RSK [13]. However, the inhibitory mechanism was un-
clear given TPCK did not directly affect the phospshotransferase
activity of PDK1. Here we investigated the inhibitory effects of
TPCK toward the non-PDK1 dependent kinases MSK1 and
MSK2 and found that they were TPCK sensitive. We next used
mass spectrometry to analyze AGC kinases immunoprecipitated
from TPCK-treated cells and found that TPCK-inhibited kinases
showed direct TPCK adduction at phenylalanine-directed cys-
teine (Phe–Cys) residues in their activation loops. Mutation of
the conserved cysteine or phenylalanine led to the generation
of kinases partially TPCK-resistant. This study thus describes a
primary mechanism by which TPCK inhibits speciﬁc AGC kinases
and describes novel TPCK resistant AGC kinase alleles. Further-
more we discuss the potential productivity of developing inhib-
itors such as TPCK that could simultaneously target conserved
Phe–Cys motifs in several AGC kinases. Such a drug could dam-
pen multiple signaling arms of a cell in a state of hyperactivity
and thereby reduce the chances of such cells developing resis-
tance, a major thorn in the side of targeted cancer therapies in
our emerging era of personalized medicine.lsevier B.V. All rights reserved.
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2.1. Plasmids
The plasmids encoding triple hemagglutinin (HA3)-tagged RSK1
[14] and HA-S6K1 [15] have been described. Bacterial expression
plasmids encoding GST-S6 (rat) Lys218-Lys249 [16], GST-BAD
[16], GST-RSK1-D1 K/R have been described. Myc-tagged PDK1 in
pCDNA3 was a gift of P. Hawkins. HA-Akt in pCMV6 was a gift of
P. Tsichlis. Flag-tagged MSK1 was a gift of R. Janknecht. The cloning
of HA3-MSK2 was as follows: EST clone AA576979 from Genome
Systems was used to generate a 32P-labeled probe that was used
to screen 1.7  106 plaques from a human T-cell cDNA library in
Lambda ZAPII (Stratagene) at 45,000 plaques per 15 cm dish. The
primers used to generate the probe were 50-GCTCAGAGCTG-
GATGTGG-30 (sense) and 50-TCGGCGTACAGGATGTTC-30 (anti-
sense). Twelve positive clones were ultimately identiﬁed and the
longest clone contained the start codon and extended 1,9000 bp
and included an internal NotI site. The 30-end of MSK2 from the
internal NotI site and extending past the stop codon 600 bp was
obtained fromGenome Systems EST clone AI831613. The full length
sequence was assembled ﬁrst in pBluescript SK-. The 50-untrans-
lated region was removed while inserting a BglII site at the 50-end
using PCR ampliﬁcation from the initiating codon and past an inter-
nal EcoRI site. The PCR primers were 50-AGAGATCTATGGGGGAC-
GAGGACGAC-30 (sense) and 50- GGAATTCTTAGGAGGGGGGCAGGG
GGCCGTT-30 (anti-sense). The 50-BglII, 30-EcoRI fragment was sub-
cloned into the BamHI, EcoRI sites of pKH3 in frame with the triple
HA-tag (at the 50-end). The remainder of MSK2 (from the internal
EcoRI site, past the stop codon and including the 30 untranslated re-
gion to an EcoRI site in pBluescript) was subcloned into the pKH3
that already contained the BglII-EcoRI fragment of MSK2 described
above, using the EcoRI fragment excised from pBluescript-MSK2.
The insert was sequenced and we found all nucleotides to be iden-
tical to those published under GenBank accession AJ010119 except
for a T2237C (numbering is from AJ010119) substitution that did
not change the amino acid sequence.2.2. Mammalian cell culture, transfection and lysis
E1 A-transformed Human embryonic kidney (HEK 293E) cells
were cultured in Dulbecco’smodiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% FBS, penicillin and streptomycin. HEK293E
cells were transfected using calcium phosphate precipitation.
Twenty four hours post-transfection, cells were starved in DMEM
containing 20 mM HEPES for 16–18 h prior to stimulation and as
indicated in the ﬁgure legends. After stimulation, cells werewashed
twice with cold phosphate-buffered saline (PBS) and then lysed in
10 mM KPO4, 1 mM EDTA, 10 mM MgCl2, 50 mM b-glycerophos-
phate, 5 mM EGTA, 0.5% Nonidet P-40, 0.1% Brij 35, 0.1% deoxychol-
ic acid, 1 mM sodium orthovanadate, 1mM phenylmethylsulfonyl
ﬂuoride, 5 lg/ml leupeptin, 5 lg/ml of pepstatin A. The cell extracts
generatedwere centrifuged at 14,000 rpm for 10 min to remove cell
debris and the clariﬁed supernatantwas used for immunoprecipita-
tions, immunoblotting or protein kinase assays.Fig. 1. TPCK inhibits PDK1-dependent and PDK1-independent AGC kinases (A)
TPCK inhibits the PDK1-dependent kinases RSK, Akt and S6K1 (A and B) as well as
the non-PDK1-dependent AGC kinase MSK1 and MSK2 (C) without inhibiting PDK1
kinase activity. HEK293E cells were serum-starved for 18 h, and treated with either
EGF (50 ng/ml) for 10 min. or Insulin (100 nM) for 30 min. (as indicated) with or
without pretreatment of cells with TPCK for 30 min. as indicated. Endogenous
kinases (RSK1, MSK1, Akt1 and S6K1) or exogenous kinases (HA-MSK2 and Myc-
PDK1) were immunoprecipitated with their respective antibodies. These immuno-
precipitates were incubated with either GST-S6, GST-Bad or GST-RSK-D2 K/R (as
indicated) in a kinase reaction containing [c  32P] ATP for 10 min. The samples
were subjected to SDS–PAGE, and the gel was autoradiographed. The lysates were
immunoblotted for pAkt, pS6, ERK1/2, HA or Myc as indicated.2.3. Immunoprecipitations, kinase assays and immunoblotting
Cell lysates were incubated with endogenous or anti-epitope
tag antibodies for 2 h and then with 20 ll of a 1:1 mixture of pro-
tein G-sepharose and protein A-sepharose beads for an additional
hour at 4 C. Beads were washed three times with lysis buffer and
the immunoprecipitates were used for kinase assays or immuno-
blotting. Kinase assays for RSK1-4, MSK1-2 and S6K1 were per-
formed using GST-S6 as a substrate. Kinase assays for Akt usedGST-BAD as a substrate. Kinase assays for PDK1 used RSK-D2 K/
R as a substrate. Kinase assays were allowed to proceed for
10 min. at 30 C prior to stopping the reaction with sample buffer
as described previously [13]. The reaction products were sub-
jected to SDS–PAGE and dried gels were exposed to X-ray ﬁlm.
For immunoblots, immune complexes or cell lysates were sub-
jected to SDS–PAGE and transferred to nitrocellulose membranes.
Blocking, primary and secondary antibody incubations of immu-
noblots were performed in TBST (10 mM Tris, pH 7.4, 150 mM
NaCl and 0.1% Tween 20) supplemented with 5% (wt/vol) dry skim
milk powder. Horseradish peroxidase-conjugated donkey anti-
rabbit and anti-mouse antibodies were used to facilitate detection
by enhanced chemiluminescence (ECL) and exposure to X-ray
ﬁlm.
Fig. 2. TPCK adducts directly to RSK1, Akt1 and S6K1 at phenylalanine-directed cysteine residues in their respective activation loops. (A) TPCK directly adducts to Cys241 of
RSK 1. HEK293E cells were transfected with HA-RSK1 as indicated. Cells were starved (18 h) and stimulated with EGF (50 ng/ml) for 10 min, with or without pretreatment of
cells with 50 lM of TPCK for 30 min. RSK1 in the lysate was immunoprecipitated with a-HA antibodies and the immune complex was subjected to SDS–PAGE. The gel band
corresponding to RSK1 from cells pre-treated with TPCK and stimulated with EGF (inset, upper panel) was excised, digested with trypsin and analyzed by liquid-
chromatography tandem MS (LC-MS/MS). A part of the lysate was analyzed for RSK1 and ERK phosphorylation (inset, lower panels). Shown is a low energy collision-induced
dissociation (CID) tandem mass spectrum of a tryptic peptide from the activation loop of RSK 1 with a TPCK adduct on Cys241 indicated by an asterisk. Also indicated are the
observed and calculated masses for the triply-charged ion species. The mass difference is indicated in parts per million (ppm) mass/charge (m/z). ‘‘#’’ indicates oxidation of
methionine. (B) Cells were transfected with HA-Akt1, starved (18 h) and stimulated with Insulin (100 nM) for 30 min after pretreatment of cells with 50 lM TPCK for 30 min.
Anti-HA immune complexes were treated as in A. Shown is a low energy CID tandem mass spectrum of a tryptic peptide from the activation loop of Akt1 with a TPCK adduct
on Cys310 indicated by an asterisk. (C) Cells were transfected with HA-S6K1, starved (18 h) and stimulated with Insulin (100 nM) for 30 min after pretreatment of cells with
50 lM TPCK for 30 min. Anti-HA immune complexes were treated as in A. Shown is a low energy CID tandem mass spectrum of a tryptic peptide from the activation loop of
S6K1 with a TPCK adduct on Cys231 indicated by an asterisk.
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In-gel tryptic digests were performed as described previously
[17] and extracted peptides were subjected to LC-MS/MS in a linear
ion trap-FT (LTQ-FT) hybrid mass spectrometer (Thermo Electron,
San Jose, CA) set up as described previously [18]. Tandem mass
spectra were searched using SEQUEST against individual kinase
amino acid sequences requiring no enzyme speciﬁcity, a 20 ppm
precursormass tolerance and allowing for the following differential
mass modiﬁcations: methionine oxidation (+15.9949); phosphory-
lation on serine, threonine and tyrosine (+79.9663); acrylamide
adduction on cysteine (+71.0371); and TPCK adduction (C17H17
NO3S) on cysteine (+315.0929). The precursor mass spectra for all
peptides of Akt and S6K1 collected in the FT were observed to be
+8.5 ppm off theoretical values and thus were appropriately
adjusted.
3. Results
3.1. TPCK inhibits PDK1-dependent and PDK1-independent AGC
kinases
We demonstrated previously that TPCK inhibited the activa-
tion of the PDK1 targets RSK, Akt and S6K1 without affecting
the activity of PI3K, PDK1, PKA and ERK1/2 [13]. While the
requirement for PDK1 in PKA activation has been controversial,
the activation of the RSK-relatives MSK1 and MSK2 have been
shown to be PDK1-independent [1]. We therefore tested the ef-
fect of TPCK on the activation of MSK1 and MSK2 to determine
if TPCK’s effect on AGC kinases might be PDK1-dependent. In
Fig. 1 we ﬁrst show our evaluation of the effect of TPCK on the
activation of RSK, Akt, S6K and MSK1. Serum-starved HEK 293
cells were pre-treated with TPCK before stimulation with eitherFig. 3. Partial TPCK resistance is observed in RSK1 and MSK1 following mutation of p
transfected with either wild-type (WT) or C241A, C241S or F240L mutants of RSK1. The c
or without pretreatment with 50 lM of TPCK for 30 min. HA-RSK1 constructs were imm
kinases were analyzed in kinase assays using GST-S6 as a substrate. The lysates were
transfections were with Flag-tagged wildtype or Cys214Ala MSK1, and immunoprecip
mechanism leading to TPCK adduction.EGF or insulin. The endogenous AGC kinases were then immuno-
precipitated and their phosphotransferase activities were ana-
lyzed by kinase assays using puriﬁed substrates. TPCK robustly
inhibited the activation of RSK, S6K, Akt and MSK1 as shown by
their inability to phosphorylate their recombinant substrates
(Fig. 1A). We also analyzed other isoforms of RSK (2–4) and TPCK
was effective in inhibiting the kinase activity of all of them
including the phosphorylation of their N-terminal activation
loops, which are known to be phosphorylated by PDK1 (data
not shown). The effect of TPCK on the activation of MSK2 using
an HA-tagged MSK2 construct found MSK2 to be TPCK-sensitive
(Fig. 1B). We also conﬁrmed that PDK1 itself was TPCK-resistant
(Fig. 1C).
3.2. TPCK modiﬁes a conserved phenylalanine-directed cysteine
residue in the activation loop of AGC kinases
The inhibition of PDK1 signaling to its downstream targets in
the presence of TPCK without affecting the activity of PDK1 was
intriguing. We envisaged that the TPCK-mediated inhibition of
AGC kinases may be due to direct adduction of TPCK to structurally
vulnerable AGC family members. To test this we immunopuriﬁed
transfected RSK1 from TPCK-treated HEK293 cells. The immunopu-
riﬁed RSK1 was subjected to SDS-PAGE, in-gel digestion and mass
spectrometry analysis (Fig. 2A). Using a high resolution mass spec-
trometer we detected a TPCK adduct at Cys241 of RSK1 (Fig. 2A).
This result prompted us to investigate if TPCK formed adducts on
other TPCK-sensitive AGC kinases. When analyzed by mass spec-
trometry we detected TPCK adduct formation on AKT, S6K1 and
MSK1. The adduct formation occurred at Cys310 of Akt (Fig. 2B),
Cys231 of S6K1 (Fig. 2C) and Cys241 of MSK1 (data not shown).
This is the same conserved activation loop cysteine which was
found modiﬁed in RSK1.henylalanine or cysteine residues in the activation loop. (A) HEK293E cells were
ells were serum starved (18 h), and stimulated with EGF (50 ng/ml) for 10 min, with
unoprecipitated and phosphotransferase activity of wildtype and mutant HA-RSK1
immunoblotted for RSK1 and ERK1/2. (B) Cells were treated as in A except that
itations used anti-Flag resin. (C) Schematic representation showing the reaction
R. Anjum et al. / FEBS Letters 586 (2012) 3471–3476 34753.3. Partial TPCK resistance is observed in RSK1 and MSK1 following
mutation of activation of phenylalanine or cysteine residues
In order to test that the TPCK-mediated inhibition of the AGC ki-
nases is due to the modiﬁcation of the conserved cysteine residues,
we introduced either alanine- or serine-encoding missense muta-
tions at Cys241 of RSK1.We also generated a RSK1 construct encod-
ing a phenylalanine to leucine mutation at Phe240. Each of these
mutations led to partial TPCK resistance with the Cys241 Ala exhib-
iting the most resistance (Fig. 3A). Furthermore, a MSK1 Cys241Ala
mutant exhibited almost complete resistance to the inhibitory ef-
fect of TPCK (Fig. 3B). The kinases Akt and S6K1, on the other hand,
become catalytically inactive upon mutation of the activation loop
cysteine residue (data not shown), making it impossible to test the
extent of TPCK inhibition on thesemutant kinases. Nevertheless, to-
gether these data suggest that TPCK adduction to phenylalanine-di-
rected cysteine residues in the activation loops of most AGC kinases
is the primary means of their inhibition by TPCK. The proposed
reaction mechanism of TPCK adduction to cysteine is presented in
Fig. 3C and is consistent with the adduct we identiﬁed using high
resolution mass spectrometry.Fig. 4. Multiple sequence alignment of all human kinases with Phe–Cys motifs in
their activation loops. The black bar denotes the Phe–Cys motif with the black
arrow denoting the site of TPCK adduction to cysteine residues. The Gray arrow
indicates the site of activation loop phosphorylation. The asterisk indicates amino
acid identity, while ‘‘.’’ and ‘‘:’’ indicate increasing levels of amino acid conservation.4. Discussion
Approaches toward personalized medicine are becoming
increasingly attractive and variably pursued. However, in chal-
lenges such as cancers, even exquisitely personalized therapies
can suffer setbacks due to resistance. A striking example of this is
the development and administration of the active BRaf inhibitor,
PLX4032, which has high selectivity and therapeutic potential
against tumors with the speciﬁc BRaf Val600Glu mutation [19].
While PLX4032 has shown dramatic BRafV600E-positive tumor
reduction in only a very few weeks [19], cancer resistance to the
drug is the dominant outcome [20]. Generally, when resistance
emerges a common counter measure is a treatment regime using
cocktails of inhibitors, thereby targeting multiple steps in the
hyperactive pathway [21].
PDK1 lies at the apex of several arms of tumorigenic pathways
given its critical role in the activation of RSK, Akt, PKC, SGK and
S6K. These pathways are signiﬁcantly intertwined and cross-talk
and compensatory mechanisms are now beginning to be under-
stood [22]. Drugs that could simultaneous dismantle these path-
ways theoretically could have signiﬁcant advantages. One type of
cancer resistance can be the upregulation of a parallel pathway to
overcome the inhibition of the targeted pathway. This can easily
be understood in terms of the difference between effects due to
endogenous or overexpressed kinases. For example, when deter-
mining if a particular kinase is responsible for the phosphorylation
of a given target three important tools are commonly used: overex-
pression, RNAi-mediated silencing and pharmacological inhibition.
This is because if the overexpressed kinase causes the substrate in
question to be phosphorylated this is useful in that it denotes that
the kinase can lead to that substrate’s phosphorylation, but the
invariable and important next question is whether or not that effect
is an ‘‘artifact’’ of overexpression, meaning a ‘‘normal’’ cell may not
behave that way. Understanding normal cell biology is of great
importance but cancer cells are not ‘‘normal’’ cells and obviously
need to be treated for what they have become and not for what they
oncewere. Thus, if a cancer cell is being driven by hyperactive PI3K-
Akt signaling and a PI3K inhibitor successfully dampens Akt
activity, the cancer might, for example, evolve to acquire hyperac-
tive RSK activity and now RSK begins to ‘‘abnormally’’ phosphory-
late Akt substrates as compensatory mechanism directed at
maintaining the survival and proliferative capacity of the tumor cell
[22]. In spite of the discussion of potential side-effects, the recentdevelopment of PDK1-speciﬁc inhibitors [23–25] is of great interest
and have been the subject of several interesting articles [10–12].
We have shown that TPCK adducts to and inhibits the activation
of PDK1-dependent (as well as PDK1-independent) AGC kinases
with Phe–Cys motifs in their activation loops. An exhaustive search
of the human kinome [26] for Phe–Cys-containing activation loops
identiﬁed eight groups within the AGC kinase family (Akt, SGK,
PKN, RSK, MSK, S6K, PKG, and PKC) and four groups within the
CamK kinase family (MARK, NIM, NuaK, TSSK and PASK) that har-
bor these motifs and thus are likely sensitive to TPCK (Fig. 4). While
inhibition of this set of kinases would certainly have pleiotropic
effects, early studies in mice prone to breast cancer exhibited
reduced tumors and no toxicity when given 1 mg per week of TPCK
for over forty weeks [27]. Furthermore, in the DMBA-insulted and
phorbol ester-promoted tumor model, TPCK greatly inhibited tu-
mor formation when applications were applied to the skin [27].
Thus, in spite of, or perhaps thanks to, TPCK’s inhibition of multiple
kinases it has shown anti-tumorigenic properties. Given TPCK’s
3476 R. Anjum et al. / FEBS Letters 586 (2012) 3471–3476ability to target multiple AGC kinases it may be less easily over-
come by cancer resistance, particularly if used as part of a chemo-
therapeutic cocktail.
Finally, the generation of TPCK-resistant alleles of AGC kinases
may providemechanisms to better decipher AGC kinase-dependent
signaling pathways in normal cells. Additionally, kinases could be
generated to become TPCK sensitive and thereby provide new tools
for signal transduction studies. In conclusion, having identiﬁed the
primarymechanism bywhich TPCK inhibits AGC kinases enlightens
both chemotherapeutic approaches as well as the use of TPCK as a
tool to understand signal transduction mechanisms.
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